The University of Chicago Header Logo

Connection

George Bakris to Angiotensin-Converting Enzyme Inhibitors

Back to Details
This is a "connection" page, showing publications George Bakris has written about Angiotensin-Converting Enzyme Inhibitors.
George Bakris
Connection Strength
16.989
Angiotensin-Converting Enzyme Inhibitors
  1. Management of Hypertension in Diabetic Nephropathy: How Low Should We Go? Blood Purif. 2016; 41(1-3):139-43.
    View in: PubMed
    Score: 0.494
  2. Effect of Patiromer on Serum Potassium Level in Patients With Hyperkalemia and Diabetic Kidney Disease: The AMETHYST-DN Randomized Clinical Trial. JAMA. 2015 Jul 14; 314(2):151-61.
    View in: PubMed
    Score: 0.477
  3. Blood pressure, hypertension, RAAS blockade, and drug therapy in diabetic kidney disease. Adv Chronic Kidney Dis. 2014 May; 21(3):281-6.
    View in: PubMed
    Score: 0.439
  4. Antihypertensive efficacy of the angiotensin receptor blocker azilsartan medoxomil compared with the angiotensin-converting enzyme inhibitor ramipril. J Hum Hypertens. 2013 Aug; 27(8):479-86.
    View in: PubMed
    Score: 0.406
  5. Pediatrics: blood pressure target for renoprotection in children. Nat Rev Nephrol. 2010 Feb; 6(2):67-8.
    View in: PubMed
    Score: 0.327
  6. Are there effects of renin-angiotensin system antagonists beyond blood pressure control? Am J Cardiol. 2010 Jan 04; 105(1 Suppl):21A-9A.
    View in: PubMed
    Score: 0.325
  7. The current state of RAAS blockade in the treatment of hypertension and proteinuria. Curr Cardiol Rep. 2009 Nov; 11(6):436-42.
    View in: PubMed
    Score: 0.321
  8. Inhibiting the renin-angiotensin system in patients with type 1 diabetes: is it worth it? Pol Arch Med Wewn. 2009 Nov; 119(11):692-3.
    View in: PubMed
    Score: 0.321
  9. Does evidence support renin-angiotensin system blockade for slowing nephropathy progression in elderly persons? Ann Intern Med. 2009 May 19; 150(10):731-3.
    View in: PubMed
    Score: 0.311
  10. Are renin-angiotensin-aldosterone system blockers distinguishable based on cardiovascular and renal outcomes in nephropathy? Postgrad Med. 2009 Mar; 121(2):77-88.
    View in: PubMed
    Score: 0.307
  11. Renin-angiotensin blockade and kidney disease. Lancet. 2008 Aug 16; 372(9638):511-2.
    View in: PubMed
    Score: 0.295
  12. Newer combination therapies in the management of hypertension: an update. J Clin Hypertens (Greenwich). 2008 May; 10(5):398-405.
    View in: PubMed
    Score: 0.289
  13. Effects of different ACE inhibitor combinations on albuminuria: results of the GUARD study. Kidney Int. 2008 Jun; 73(11):1303-9.
    View in: PubMed
    Score: 0.287
  14. Trials that matter: the effect of a fixed-dose combination of an Angiotensin-converting enzyme inhibitor and a diuretic on the complications of type 2 diabetes. Ann Intern Med. 2008 Mar 04; 148(5):400-1.
    View in: PubMed
    Score: 0.286
  15. Slowing nephropathy progression: focus on proteinuria reduction. Clin J Am Soc Nephrol. 2008 Jan; 3 Suppl 1:S3-10.
    View in: PubMed
    Score: 0.283
  16. Treatment of microalbuminuria in hypertensive subjects with elevated cardiovascular risk: results of the IMPROVE trial. Kidney Int. 2007 Oct; 72(7):879-85.
    View in: PubMed
    Score: 0.275
  17. ACE inhibitors and ARBs: are they better than other agents to slow nephropathy progression? J Clin Hypertens (Greenwich). 2007 Jun; 9(6):413-5.
    View in: PubMed
    Score: 0.272
  18. The continuum of blood pressure risk: when is the best time to intervene? Curr Hypertens Rep. 2006 Oct; 8(5):395-7.
    View in: PubMed
    Score: 0.259
  19. Rationale and design of a study comparing two fixed-dose combination regimens to reduce albuminuria in patients with type II diabetes and hypertension. J Hum Hypertens. 2005 Feb; 19(2):139-44.
    View in: PubMed
    Score: 0.231
  20. ACE inhibitor for a diabetic patient with normal blood pressure? Postgrad Med. 2005 Jan; 117(1):6.
    View in: PubMed
    Score: 0.230
  21. Effect of fixed-dose ACE-inhibitor/calcium channel blocker combination therapy vs. ACE-inhibitor monotherapy on arterial compliance in hypertensive patients with type 2 diabetes. Prev Cardiol. 2005; 8(2):87-92.
    View in: PubMed
    Score: 0.230
  22. The JNC 7 approach compared to conventional treatment in diabetic patients with hypertension: a double-blind trial of initial monotherapy vs. combination therapy. J Clin Hypertens (Greenwich). 2004 Aug; 6(8):437-42; quiz 443-4.
    View in: PubMed
    Score: 0.223
  23. Amlodipine/benazepril combination therapy for hypertensive patients nonresponsive to benazepril monotherapy. Am J Hypertens. 2004 Jul; 17(7):590-6.
    View in: PubMed
    Score: 0.222
  24. How to adjust ACE inhibitors and ARBs in diabetes? Postgrad Med. 2004 May; 115(5):9-10.
    View in: PubMed
    Score: 0.219
  25. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in chronic renal disease: safety issues. Semin Nephrol. 2004 Mar; 24(2):168-75.
    View in: PubMed
    Score: 0.217
  26. The role of calcium antagonists in chronic kidney disease. Curr Opin Nephrol Hypertens. 2004 Mar; 13(2):155-61.
    View in: PubMed
    Score: 0.217
  27. Clinical implications of blockade of the renin-angiotensin system in management of hypertension. Contrib Nephrol. 2004; 143:105-16.
    View in: PubMed
    Score: 0.214
  28. How high should an ACE inhibitor or angiotensin receptor blocker be dosed in patients with diabetic nephropathy? Curr Hypertens Rep. 2003 Oct; 5(5):418-25.
    View in: PubMed
    Score: 0.211
  29. Slowing the Progression of Diabetic Kidney Disease. Cells. 2023 07 31; 12(15).
    View in: PubMed
    Score: 0.208
  30. ACE inhibitors and protection against kidney disease progression in patients with type 2 diabetes: what's the evidence. J Clin Hypertens (Greenwich). 2002 Nov-Dec; 4(6):420-3.
    View in: PubMed
    Score: 0.198
  31. Comparison of telmisartan vs. valsartan in the treatment of mild to moderate hypertension using ambulatory blood pressure monitoring. J Clin Hypertens (Greenwich). 2002 Jul-Aug; 4(4 Suppl 1):26-31.
    View in: PubMed
    Score: 0.193
  32. Angiotensin converting enzyme inhibitors or angiotensin receptor blockers in nephropathy from type 2 diabetes. Curr Hypertens Rep. 2002 Jun; 4(3):185-90.
    View in: PubMed
    Score: 0.192
  33. Impact of an ACE inhibitor and calcium antagonist on microalbuminuria and lipid subfractions in type 2 diabetes: a randomised, multi-centre pilot study. J Hum Hypertens. 2002 Mar; 16(3):185-91.
    View in: PubMed
    Score: 0.189
  34. Mineralocorticoid receptor antagonists in diabetic kidney disease - mechanistic and therapeutic effects. Nat Rev Nephrol. 2022 01; 18(1):56-70.
    View in: PubMed
    Score: 0.184
  35. Angiotensin-converting enzyme inhibition to enhance vascular health--clinical and research models. Am J Hypertens. 2001 Aug; 14(8 Pt 2):264S-269S.
    View in: PubMed
    Score: 0.181
  36. Cardiovascular Benefits of Angiotensin-Converting Enzyme Inhibition Plus Calcium Channel Blockade in Patients Achieving Tight Blood Pressure Control and With Resistant Hypertension. Am J Hypertens. 2021 05 22; 34(5):531-539.
    View in: PubMed
    Score: 0.179
  37. ACE inhibition or angiotensin receptor blockade: impact on potassium in renal failure. VAL-K Study Group. Kidney Int. 2000 Nov; 58(5):2084-92.
    View in: PubMed
    Score: 0.172
  38. Non-steroidal mineralocorticoid antagonists: Prospects for renoprotection in diabetic kidney disease. Diabetes Obes Metab. 2020 04; 22 Suppl 1:69-76.
    View in: PubMed
    Score: 0.165
  39. Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern? Arch Intern Med. 2000 Mar 13; 160(5):685-93.
    View in: PubMed
    Score: 0.165
  40. Benefits of combination angiotensin-converting enzyme inhibitor and calcium antagonist therapy for diabetic patients. Am J Hypertens. 1999 Aug; 12(8 Pt 2):80S-85S.
    View in: PubMed
    Score: 0.158
  41. When to discontinue ACE inhibitors for nephropathy. Postgrad Med. 1999 Jul; 106(1):29.
    View in: PubMed
    Score: 0.157
  42. Effects of an ACE inhibitor/calcium antagonist combination on proteinuria in diabetic nephropathy. Kidney Int. 1998 Oct; 54(4):1283-9.
    View in: PubMed
    Score: 0.149
  43. Long-term effects of patiromer for hyperkalaemia treatment in patients with mild heart failure and diabetic nephropathy on angiotensin-converting enzymes/angiotensin receptor blockers: results from AMETHYST-DN. ESC Heart Fail. 2018 08; 5(4):592-602.
    View in: PubMed
    Score: 0.145
  44. Prior Medications and the Cardiovascular Benefits From Combination Angiotensin-Converting Enzyme Inhibition Plus Calcium Channel Blockade Among High-Risk Hypertensive Patients. J Am Heart Assoc. 2018 01 04; 7(1).
    View in: PubMed
    Score: 0.142
  45. Effect of Patiromer on Hyperkalemia Recurrence in Older Chronic Kidney Disease Patients Taking RAAS Inhibitors. Am J Med. 2018 05; 131(5):555-564.e3.
    View in: PubMed
    Score: 0.140
  46. Combined effects of an angiotensin converting enzyme inhibitor and a calcium antagonist on renal injury. J Hypertens. 1997 Oct; 15(10):1181-5.
    View in: PubMed
    Score: 0.139
  47. Effects of an ACE inhibitor combined with a calcium channel blocker on progression of diabetic nephropathy. J Hum Hypertens. 1997 Jan; 11(1):35-8.
    View in: PubMed
    Score: 0.132
  48. Mineralocorticoid antagonists in chronic kidney disease. Curr Opin Nephrol Hypertens. 2017 01; 26(1):50-55.
    View in: PubMed
    Score: 0.132
  49. Angiotensin-Converting Enzyme Inhibitor Use and Major Cardiovascular Outcomes in Type 2 Diabetes Mellitus Treated With the Dipeptidyl Peptidase 4 Inhibitor Alogliptin. Hypertension. 2016 09; 68(3):606-13.
    View in: PubMed
    Score: 0.128
  50. Current issues in treating the hypertensive patient with diabetes: focus on diabetic nephropathy. Ann Pharmacother. 1996 Jul-Aug; 30(7-8):791-801.
    View in: PubMed
    Score: 0.127
  51. New approaches to hyperkalemia in patients with indications for renin angiotensin aldosterone inhibitors: Considerations for trial design and regulatory approval. Int J Cardiol. 2016 Aug 01; 216:46-51.
    View in: PubMed
    Score: 0.126
  52. Has RAAS Blockade Reached Its Limits in the Treatment of Diabetic Nephropathy? Curr Diab Rep. 2016 Apr; 16(4):24.
    View in: PubMed
    Score: 0.125
  53. Effects of ACE inhibitors and calcium antagonists alone or combined on progression of diabetic nephropathy. Nephrol Dial Transplant. 1995 Oct; 10 Suppl 9:56-62.
    View in: PubMed
    Score: 0.121
  54. Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy: A Randomized Clinical Trial. JAMA. 2015 Sep 01; 314(9):884-94.
    View in: PubMed
    Score: 0.120
  55. Angiotensin converting enzyme inhibitors and calcium antagonists alone or combined: does the progression of diabetic renal disease differ? J Hypertens Suppl. 1995 Aug; 13(2):S95-101.
    View in: PubMed
    Score: 0.120
  56. Rationale, design, and baseline characteristics of ARTS-DN: a randomized study to assess the safety and efficacy of finerenone in patients with type 2 diabetes mellitus and a clinical diagnosis of diabetic nephropathy. Am J Nephrol. 2014; 40(6):572-81.
    View in: PubMed
    Score: 0.115
  57. ACE inhibitor-mediated attenuation of mesangial cell growth. A role for endothelin. Am J Hypertens. 1994 Jul; 7(7 Pt 1):583-90.
    View in: PubMed
    Score: 0.111
  58. Prediction and management of hyperkalemia across the spectrum of chronic kidney disease. Semin Nephrol. 2014 May; 34(3):333-9.
    View in: PubMed
    Score: 0.109
  59. Long-term effects of antihypertensive regimens on renal hemodynamics and proteinuria. Kidney Int. 1993 Jun; 43(6):1210-8.
    View in: PubMed
    Score: 0.103
  60. Effects of nebivolol on aortic compliance in patients with diabetes and maximal renin angiotensin system blockade: the EFFORT study. J Clin Hypertens (Greenwich). 2013 Jul; 15(7):473-9.
    View in: PubMed
    Score: 0.102
  61. Angiotensin-converting enzyme inhibitors and progression of diabetic nephropathy. Ann Intern Med. 1993 Apr 15; 118(8):643-4.
    View in: PubMed
    Score: 0.102
  62. The past, present and future of renin-angiotensin aldosterone system inhibition. Int J Cardiol. 2013 Sep 01; 167(5):1677-87.
    View in: PubMed
    Score: 0.099
  63. Management of hypertension in the elderly population. J Gerontol A Biol Sci Med Sci. 2012 Dec; 67(12):1343-51.
    View in: PubMed
    Score: 0.098
  64. Renin-angiotensin inhibition in systolic heart failure and chronic kidney disease. Am J Med. 2012 Apr; 125(4):399-410.
    View in: PubMed
    Score: 0.094
  65. A perspective on converting enzyme inhibitors and calcium channel antagonists in diabetic renal disease. Arch Intern Med. 1991 Dec; 151(12):2367-72.
    View in: PubMed
    Score: 0.093
  66. Fixed-dose combination and chronic kidney disease progression: which is the best? Curr Opin Nephrol Hypertens. 2010 Sep; 19(5):450-5.
    View in: PubMed
    Score: 0.085
  67. Dual RAAS blockade is desirable in kidney disease: con. Kidney Int. 2010 Sep; 78(6):546-9.
    View in: PubMed
    Score: 0.084
  68. Cardiovascular events during differing hypertension therapies in patients with diabetes. J Am Coll Cardiol. 2010 Jun 29; 56(1):77-85.
    View in: PubMed
    Score: 0.084
  69. Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial. Lancet. 2010 Apr 03; 375(9721):1173-81.
    View in: PubMed
    Score: 0.082
  70. Predictors of hyperkalemia risk following hypertension control with aldosterone blockade. Am J Nephrol. 2009; 30(5):418-24.
    View in: PubMed
    Score: 0.079
  71. Should proteinuria reduction be the criterion for antihypertensive drug selection for patients with kidney disease? Curr Opin Nephrol Hypertens. 2009 Sep; 18(5):386-91.
    View in: PubMed
    Score: 0.079
  72. Monitoring and managing urinary albumin excretion: practical advice for primary care clinicians. Postgrad Med. 2009 Jul; 121(4):51-60.
    View in: PubMed
    Score: 0.078
  73. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med. 2008 Dec 04; 359(23):2417-28.
    View in: PubMed
    Score: 0.075
  74. Resistant hypertension: an overview of evaluation and treatment. J Am Coll Cardiol. 2008 Nov 25; 52(22):1749-57.
    View in: PubMed
    Score: 0.075
  75. Changes in kidney function following heart failure treatment: focus on renin-angiotensin system blockade. Heart Fail Clin. 2008 Oct; 4(4):425-38.
    View in: PubMed
    Score: 0.074
  76. Influence of microalbuminuria in achieving blood pressure goals. Curr Opin Nephrol Hypertens. 2008 Sep; 17(5):457-63.
    View in: PubMed
    Score: 0.074
  77. Long-term effects of renin-angiotensin system-blocking therapy and a low blood pressure goal on progression of hypertensive chronic kidney disease in African Americans. Arch Intern Med. 2008 Apr 28; 168(8):832-9.
    View in: PubMed
    Score: 0.072
  78. Comparison of dual RAAS blockade and higher-dose RAAS inhibition on nephropathy progression. Postgrad Med. 2008 Apr; 120(1):33-42.
    View in: PubMed
    Score: 0.072
  79. Combination therapy with Renin-Angiotensin-aldosterone receptor blockers for hypertension: how far have we come? J Clin Hypertens (Greenwich). 2008 Feb; 10(2):146-52.
    View in: PubMed
    Score: 0.071
  80. Combined therapy with a calcium channel blocker and an angiotensin II type 1 receptor blocker. J Clin Hypertens (Greenwich). 2008 Jan; 10(1 Suppl 1):27-32.
    View in: PubMed
    Score: 0.071
  81. Blood pressure control in the patient with difficult-to-control hypertension: which agent for which patient? Prev Cardiol. 2008; 11(1):42-9.
    View in: PubMed
    Score: 0.071
  82. The diabetes subgroup baseline characteristics of the Avoiding Cardiovascular Events Through Combination Therapy in Patients Living With Systolic Hypertension (ACCOMPLISH) trial. J Cardiometab Syndr. 2008; 3(4):229-33.
    View in: PubMed
    Score: 0.071
  83. Lowering blood pressure with beta-blockers in combination with other renin-angiotensin system blockers in patients with hypertension and type 2 diabetes: results from the GEMINI Trial. J Clin Hypertens (Greenwich). 2007 Nov; 9(11):842-9.
    View in: PubMed
    Score: 0.070
  84. Angiotensin-converting enzyme gene polymorphism predicts the time-course of blood pressure response to angiotensin converting enzyme inhibition in the AASK trial. J Hypertens. 2007 Oct; 25(10):2082-92.
    View in: PubMed
    Score: 0.069
  85. Antihypertensive therapy in the presence of proteinuria. Am J Kidney Dis. 2007 Jan; 49(1):12-26.
    View in: PubMed
    Score: 0.066
  86. Dual therapy in hypertensive patients with coronary artery disease: the role of calcium channel blockers and beta-blockers. Am J Cardiovasc Drugs. 2007; 7 Suppl 1:25-9.
    View in: PubMed
    Score: 0.066
  87. Antihypertensive treatment with beta-blockers and the spectrum of glycaemic control. QJM. 2006 Jul; 99(7):431-6.
    View in: PubMed
    Score: 0.063
  88. Rationale and design of a study to evaluate management of proteinuria in patients at high risk for vascular events: the IMPROVE trial. J Hum Hypertens. 2006 Sep; 20(9):693-700.
    View in: PubMed
    Score: 0.063
  89. Is ethnicity a factor in choice of antihypertensive drug? Postgrad Med. 2005 May; 117(5):40.
    View in: PubMed
    Score: 0.059
  90. The relationship between magnitude of proteinuria reduction and risk of end-stage renal disease: results of the African American study of kidney disease and hypertension. Arch Intern Med. 2005 Apr 25; 165(8):947-53.
    View in: PubMed
    Score: 0.059
  91. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. JAMA. 2004 Nov 10; 292(18):2227-36.
    View in: PubMed
    Score: 0.057
  92. Implications of albuminuria on kidney disease progression. J Clin Hypertens (Greenwich). 2004 Nov; 6(11 Suppl 3):18-22.
    View in: PubMed
    Score: 0.057
  93. Clinical importance of microalbuminuria in diabetes and hypertension. Curr Hypertens Rep. 2004 Oct; 6(5):352-6.
    View in: PubMed
    Score: 0.056
  94. Clinical outcomes in the diabetes cohort of the INternational VErapamil SR-Trandolapril study. Hypertension. 2004 Nov; 44(5):637-42.
    View in: PubMed
    Score: 0.056
  95. Blood pressure control and nephroprotection in diabetes. J Clin Pharmacol. 2004 Apr; 44(4):431-8.
    View in: PubMed
    Score: 0.055
  96. Effects of COX inhibition on blood pressure and kidney function in ACE inhibitor-treated blacks and hispanics. Hypertension. 2004 Mar; 43(3):573-7.
    View in: PubMed
    Score: 0.054
  97. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA. 2003 Dec 03; 290(21):2805-16.
    View in: PubMed
    Score: 0.053
  98. Who should be treated with combination therapy as initial treatment for hypertension? J Clin Hypertens (Greenwich). 2003 Jul-Aug; 5(4 Suppl 3):21-8.
    View in: PubMed
    Score: 0.052
  99. Defining the antihypertensive properties of the angiotensin receptor blocker telmisartan by a practice-based clinical trial. Am J Hypertens. 2003 Jun; 16(6):460-6.
    View in: PubMed
    Score: 0.051
  100. The evolution of treatment guidelines for diabetic nephropathy. Strategies integrate JNC VI, more recent protocols. Postgrad Med. 2003 May; 113(5):35-40, 43-4, 50.
    View in: PubMed
    Score: 0.051
  101. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA. 2002 Nov 20; 288(19):2421-31.
    View in: PubMed
    Score: 0.050
  102. Optimal treatment of hypertension in African Americans. Reaching and maintaining target blood pressure goals. Postgrad Med. 2002 Oct; 112(4):73-4, 77-80, 83-4.
    View in: PubMed
    Score: 0.049
  103. Evaluation and treatment of patients with systemic hypertension. Circulation. 2002 May 28; 105(21):2458-61.
    View in: PubMed
    Score: 0.048
  104. Type 2 diabetes: RENAAL and IDNT--the emergence of new treatment options. J Clin Hypertens (Greenwich). 2002 Jan-Feb; 4(1):52-7.
    View in: PubMed
    Score: 0.047
  105. Treatment of the diabetic patient: focus on cardiovascular and renal risk reduction. Prog Brain Res. 2002; 139:289-98.
    View in: PubMed
    Score: 0.047
  106. A practical approach to achieving recommended blood pressure goals in diabetic patients. Arch Intern Med. 2001 Dec 10-24; 161(22):2661-7.
    View in: PubMed
    Score: 0.046
  107. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. JAMA. 2001 Jun 06; 285(21):2719-28.
    View in: PubMed
    Score: 0.045
  108. Evolution of drugs that preserve renal function. J Clin Pharmacol. 2000 Sep; 40(9):978-89.
    View in: PubMed
    Score: 0.043
  109. Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am J Kidney Dis. 2000 Sep; 36(3):646-61.
    View in: PubMed
    Score: 0.043
  110. Antihypertensive therapy and the risk of type 2 diabetes mellitus. N Engl J Med. 2000 Mar 30; 342(13):969-70.
    View in: PubMed
    Score: 0.041
  111. Baseline characteristics and enrichment results from the SONAR trial. Diabetes Obes Metab. 2018 08; 20(8):1829-1835.
    View in: PubMed
    Score: 0.036
  112. Effect of antihypertensive treatment on 24-h blood pressure variability: pooled individual data analysis of ambulatory blood pressure monitoring studies based on olmesartan mono or combination treatment. J Hypertens. 2018 04; 36(4):720-733.
    View in: PubMed
    Score: 0.036
  113. Rationale and protocol of the Study Of diabetic Nephropathy with AtRasentan (SONAR) trial: A clinical trial design novel to diabetic nephropathy. Diabetes Obes Metab. 2018 06; 20(6):1369-1376.
    View in: PubMed
    Score: 0.036
  114. Diabetic hypertensive patients: improving their prognosis. J Cardiovasc Pharmacol. 1998; 31 Suppl 2:S34-40.
    View in: PubMed
    Score: 0.035
  115. Treatment of renal failure and blood pressure. Curr Opin Nephrol Hypertens. 1997 May; 6(3):237-42.
    View in: PubMed
    Score: 0.034
  116. Renal mortality associated with non-insulin-dependent diabetes mellitus. J Diabetes Complications. 1997 Mar-Apr; 11(2):104-11.
    View in: PubMed
    Score: 0.033
  117. Socioeconomic impact of diabetic nephropathy: can we improve the outcome? J Hypertens Suppl. 1997 Mar; 15(2):S77-82.
    View in: PubMed
    Score: 0.033
  118. Treatment with patiromer decreases aldosterone in patients with chronic kidney disease and hyperkalemia on renin-angiotensin system inhibitors. Kidney Int. 2016 09; 90(3):696-704.
    View in: PubMed
    Score: 0.032
  119. Effects of aliskiren in diabetic and non-diabetic patients with coronary artery disease: Insights from AQUARIUS. Atherosclerosis. 2015 Dec; 243(2):553-9.
    View in: PubMed
    Score: 0.030
  120. Effect of patiromer on reducing serum potassium and preventing recurrent hyperkalaemia in patients with heart failure and chronic kidney disease on RAAS inhibitors. Eur J Heart Fail. 2015 Oct; 17(10):1057-65.
    View in: PubMed
    Score: 0.030
  121. Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors. N Engl J Med. 2015 Jan 15; 372(3):211-21.
    View in: PubMed
    Score: 0.028
  122. Renal adaptation to the failing heart. Avoiding a 'therapeutic misadventure'. Postgrad Med. 1994 Jun; 95(8):153-6.
    View in: PubMed
    Score: 0.028
  123. The contribution of the ACCOMPLISH trial to the treatment of stage 2 hypertension. Curr Hypertens Rep. 2014 Mar; 16(3):419.
    View in: PubMed
    Score: 0.027
  124. Antihypertensive therapy and progression of diabetic renal disease. J Cardiovasc Pharmacol. 1994; 23 Suppl 1:S34-8.
    View in: PubMed
    Score: 0.027
  125. Renal effects of antihypertensive medications: an overview. J Clin Pharmacol. 1993 May; 33(5):392-9.
    View in: PubMed
    Score: 0.026
  126. Treatment of arterial hypertension in diabetic humans: importance of therapeutic selection. Kidney Int. 1992 Apr; 41(4):912-9.
    View in: PubMed
    Score: 0.024
  127. Renal outcomes in hypertensive Black patients at high cardiovascular risk. Kidney Int. 2012 Mar; 81(6):568-76.
    View in: PubMed
    Score: 0.023
  128. The effects of calcium antagonists on renal hemodynamics, urinary protein excretion, and glomerular morphology in diabetic states. J Am Soc Nephrol. 1991 Aug; 2(2 Suppl 1):S21-9.
    View in: PubMed
    Score: 0.023
  129. Intensive blood-pressure control in hypertensive chronic kidney disease. N Engl J Med. 2010 Sep 02; 363(10):918-29.
    View in: PubMed
    Score: 0.021
  130. 24-hour ambulatory blood pressure in the ACCOMPLISH trial. N Engl J Med. 2010 Jul 01; 363(1):98.
    View in: PubMed
    Score: 0.021
  131. Effects of diltiazem or lisinopril on massive proteinuria associated with diabetes mellitus. Ann Intern Med. 1990 May 01; 112(9):707-8.
    View in: PubMed
    Score: 0.021
  132. Combination therapy in hypertension. J Am Soc Hypertens. 2010 Jan-Feb; 4(1):42-50.
    View in: PubMed
    Score: 0.020
  133. The evolution of antihypertensive therapy: an overview of four decades of experience. J Am Coll Cardiol. 1989 Dec; 14(7):1595-608.
    View in: PubMed
    Score: 0.020
  134. Risk of hyperkalemia in nondiabetic patients with chronic kidney disease receiving antihypertensive therapy. Arch Intern Med. 2009 Sep 28; 169(17):1587-94.
    View in: PubMed
    Score: 0.020
  135. Efficacy and safety of darusentan in patients with resistant hypertension: results from a randomized, double-blind, placebo-controlled dose-ranging study. J Clin Hypertens (Greenwich). 2007 Oct; 9(10):760-9.
    View in: PubMed
    Score: 0.017
  136. The kidney and cardiovascular risk--implications for management: a consensus statement from the European Society of Hypertension. Blood Press. 2007; 16(2):72-9.
    View in: PubMed
    Score: 0.016
  137. Intervention at lower blood pressure levels to achieve target goals in type 2 diabetes: PRADID (PResión Arterial en DIabéticos tipo Dos) study. J Hypertens. 2004 Jan; 22(1):217-22.
    View in: PubMed
    Score: 0.013
  138. Quality of life measured in a practice-based hypertension trial of an angiotensin receptor blocker. J Clin Hypertens (Greenwich). 2003 Sep-Oct; 5(5):322-9.
    View in: PubMed
    Score: 0.013
  139. Design and statistical aspects of the African American Study of Kidney Disease and Hypertension (AASK). J Am Soc Nephrol. 2003 Jul; 14(7 Suppl 2):S154-65.
    View in: PubMed
    Score: 0.013
  140. Heart failure as a cause for hospitalization in chronic dialysis patients. Am J Kidney Dis. 2003 Jun; 41(6):1267-77.
    View in: PubMed
    Score: 0.013
  141. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003 May 21; 289(19):2560-72.
    View in: PubMed
    Score: 0.013
  142. Lack of evidence of blood pressure-independent protection by renin-angiotensin system blockade after renal ablation. Kidney Int. 2000 Apr; 57(4):1651-61.
    View in: PubMed
    Score: 0.010
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.